SanegeneBio Raises over $110 Million in Series B Financing

BOSTON, SHANGHAI, and SUZHOU — December 8, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced the closing of Series B financing round, raising over $110 million. The financing will advance its clinical stage assets towards registrational studies and accelerate the development of programs across several therapeutic areas, powered by its industry-leading RNAi technologies including the LEAD™ (Ligand and Enhancer Assisted Delivery) delivery platform.

The Series B financing was led by a well-known industrial investor, with participation from an international sovereign wealth fund, Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital, TruMed, and Lake Bleu Capital; strategic investment from Eli Lilly and Company; and continued support from existing shareholders including Qiming Venture Partners, K2 Venture Partners, TF Capital, Oriza Holdings, Northern Light Venture Capital, among others.

Since its inception in 2021, SanegeneBio has established proprietary RNAi platform enabling first- or best-in-class RNAi therapeutics targeting both liver and extrahepatic tissues, based on which it has built a diversified pipeline including multiple clinical-stage programs across autoimmune, cardiovascular, metabolic diseases and obesity. The successful completion of the Series B financing will further accelerate and globally expand ongoing and planned clinical studies, while supporting continued breakthroughs in RNAi technology.

Dr. Weimin Wang, Founder and Chief Executive Officer of SanegeneBio, stated:

• “The successful closing of the Series B round represents a significant milestone in SanegeneBio's development footprint. We are honored to have the support from leading global institutional investors, showing their confidence and recognition of our R&D strength and corporate vision, while providing important resources for our long-term growth. We remain committed to addressing global unmet medical needs by continuously innovating to expand the frontier of RNAi technologies. Moving forward, we plan to advance our investigational medicines to late-stage development globally, and bring more transformative programs into the clinic leveraging our LEAD^TM platform .”

About SanegeneBio

SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage on LinkedIn.

Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "could," "potential," "is/are likely to," "will," "plan," "intend," "aim," "expect," "anticipate," "believe," "hope," "estimate," "project," "forecast," "continue," "target," and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements.

These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.

Medical Information
This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.